[Advances in Molecular Biomarker for Pulmonary Large Cell Neuroendocrine Carcinoma]

Overview

Journal Zhongguo Fei Ai Za Zhi

Specialties Oncology
Pulmonary Medicine

Date 2020 Nov 18

PMID 33203199

Authors

Jinyao Zhang

Lin Yang

Junling Li

Affiliations

Soon will be listed here.

Abstract

Pulmonary large cell neuroendocrine carcinoma (LCNEC) is a pathological subtype of lung neuroendocrine cancer, which accounts for 2.4%-3.1% in surgical specimens of lung cancer. It is characterized by high invasiveness and poor prognosis, and highly correlated with smoking. There are few relevant studies due to the low incidence and small sample size. Therefore, it is relatively difficult to diagnosis and treatment in clinical practice. In this review, we described molecular subtype, diagnostic and prognostic-related markers about large cell neuroendocrine carcinoma of lung based on the recent progress in genomic sequencing and molecular markers, to find the direction for the next research. .

References

Oda R, Okuda K, Yamashita Y, Sakane T, Tatematsu T, Yokota K . Long-term survivor of pulmonary combined large cell neuroendocrine carcinoma treated with nivolumab. Thorac Cancer. 2020; 11(7):2036-2039. PMC: 7327674. DOI: 10.1111/1759-7714.13471. View

Fernandez-Cuesta L, Peifer M, Lu X, Sun R, Ozretic L, Seidal D . Frequent mutations in chromatin-remodelling genes in pulmonary carcinoids. Nat Commun. 2014; 5:3518. PMC: 4132974. DOI: 10.1038/ncomms4518. View

Caplin M, Baudin E, Ferolla P, Filosso P, Garcia-Yuste M, Lim E . Pulmonary neuroendocrine (carcinoid) tumors: European Neuroendocrine Tumor Society expert consensus and recommendations for best practice for typical and atypical pulmonary carcinoids. Ann Oncol. 2015; 26(8):1604-20. DOI: 10.1093/annonc/mdv041. View

Hiroshima K, Mino-Kenudson M . Update on large cell neuroendocrine carcinoma. Transl Lung Cancer Res. 2017; 6(5):530-539. PMC: 5653527. DOI: 10.21037/tlcr.2017.06.12. View

Wijnhoven B, Dinjens W, Pignatelli M . E-cadherin-catenin cell-cell adhesion complex and human cancer. Br J Surg. 2000; 87(8):992-1005. DOI: 10.1046/j.1365-2168.2000.01513.x. View

Rittmeyer A, Barlesi F, Waterkamp D, Park K, Ciardiello F, von Pawel J . Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial. Lancet. 2016; 389(10066):255-265. PMC: 6886121. DOI: 10.1016/S0140-6736(16)32517-X. View

Christopoulos P, Schneider M, Bozorgmehr F, Kuon J, Engel-Riedel W, Kollmeier J . Large cell neuroendocrine lung carcinoma induces peripheral T-cell repertoire alterations with predictive and prognostic significance. Lung Cancer. 2018; 119:48-55. DOI: 10.1016/j.lungcan.2018.03.002. View

Derks J, Leblay N, Thunnissen E, van Suylen R, den Bakker M, Groen H . Molecular Subtypes of Pulmonary Large-cell Neuroendocrine Carcinoma Predict Chemotherapy Treatment Outcome. Clin Cancer Res. 2017; 24(1):33-42. DOI: 10.1158/1078-0432.CCR-17-1921. View

Shi M, Zhao W, Zhou F, Chen H, Tang L, Su B . Neutrophil or platelet-to-lymphocyte ratios in blood are associated with poor prognosis of pulmonary large cell neuroendocrine carcinoma. Transl Lung Cancer Res. 2020; 9(1):45-54. PMC: 7082296. DOI: 10.21037/tlcr.2020.01.17. View

10.

Henke R, Meredith D, Borromeo M, Savage T, Johnson J . Ascl1 and Neurog2 form novel complexes and regulate Delta-like3 (Dll3) expression in the neural tube. Dev Biol. 2009; 328(2):529-40. PMC: 2698949. DOI: 10.1016/j.ydbio.2009.01.007. View

11.

Travis W, Brambilla E, Burke A, Marx A, Nicholson A . Introduction to The 2015 World Health Organization Classification of Tumors of the Lung, Pleura, Thymus, and Heart. J Thorac Oncol. 2015; 10(9):1240-1242. DOI: 10.1097/JTO.0000000000000663. View

12.

Harvey K, Zhang X, Thomas D . The Hippo pathway and human cancer. Nat Rev Cancer. 2013; 13(4):246-57. DOI: 10.1038/nrc3458. View

13.

Ball D . Achaete-scute homolog-1 and Notch in lung neuroendocrine development and cancer. Cancer Lett. 2004; 204(2):159-69. DOI: 10.1016/S0304-3835(03)00452-X. View

14.

Zhuo M, Guan Y, Yang X, Hong L, Wang Y, Li Z . The Prognostic and Therapeutic Role of Genomic Subtyping by Sequencing Tumor or Cell-Free DNA in Pulmonary Large-Cell Neuroendocrine Carcinoma. Clin Cancer Res. 2019; 26(4):892-901. PMC: 7024651. DOI: 10.1158/1078-0432.CCR-19-0556. View

15.

Simbolo M, Mafficini A, Sikora K, Fassan M, Barbi S, Corbo V . Lung neuroendocrine tumours: deep sequencing of the four World Health Organization histotypes reveals chromatin-remodelling genes as major players and a prognostic role for TERT, RB1, MEN1 and KMT2D. J Pathol. 2016; 241(4):488-500. PMC: 5324596. DOI: 10.1002/path.4853. View

16.

Sherman S, Rotem O, Shochat T, Zer A, Moore A, Dudnik E . Efficacy of immune check-point inhibitors (ICPi) in large cell neuroendocrine tumors of lung (LCNEC). Lung Cancer. 2020; 143:40-46. DOI: 10.1016/j.lungcan.2020.03.008. View

17.

Brominska B, Gabryel P, Jarmolowska-Jurczyszyn D, Janicka-Jedynska M, Kluk A, Trojanowski M . Klotho expression and nodal involvement as predictive factors for large cell lung carcinoma. Arch Med Sci. 2019; 15(4):1010-1016. PMC: 6657266. DOI: 10.5114/aoms.2018.75889. View

18.

Obayashi S, Horiguchi J, Higuchi T, Katayama A, Handa T, Altan B . Stathmin1 expression is associated with aggressive phenotypes and cancer stem cell marker expression in breast cancer patients. Int J Oncol. 2017; 51(3):781-790. PMC: 5564402. DOI: 10.3892/ijo.2017.4085. View

19.

Morise M, Hishida T, Takahashi A, Yoshida J, Ohe Y, Nagai K . Clinicopathological significance of cancer stem-like cell markers in high-grade neuroendocrine carcinoma of the lung. J Cancer Res Clin Oncol. 2015; 141(12):2121-30. DOI: 10.1007/s00432-015-1985-3. View

20.

Ye B, Cappel J, Findeis-Hosey J, McMahon L, Yang Q, Xiao G . hASH1 is a specific immunohistochemical marker for lung neuroendocrine tumors. Hum Pathol. 2015; 48:142-7. DOI: 10.1016/j.humpath.2015.09.019. View